Interestingly, XBP1 can simultaneously regulate the expression of multiple immune checkpoint molecules, such as PD1, LAG3, and HAVCR2, in some types of tumours [176], suggesting that XBP1 is a potential target for overcoming immunotherapy resistance. Here, PDCD1 is linked to neoplasm.